Dermatology Times

06/22/2026

👥🎸 CONFERENCE HIGHLIGHTS: Peter Lio, MD, discussed the evolving pediatric AD landscape, emphasizing individualized care, shared decision-making, and the need for pediatric-specific guidance as new nonsteroidal topicals and systemic therapies expand treatment options.

🎥 Watch the full interview now:

Peter Lio, MD, explains how shared decision-making and newer nonsteroidal topicals and systemic options are reshaping pediatric eczema care, easing steroid worries.

06/22/2026

🚨 NEW TODAY: AbbVie’s $10.9B acquisition of Apogee Therapeutics adds investigational IL-13 antibody to its immunology pipeline. Hear more from Christopher Bunick, MD, PhD, below on what the deal could mean for the future of atopic dermatitis care.

🔗 Read more: https://hubs.li/Q04m8ywf0

06/19/2026

👥🎸 CONFERENCE HIGHLIGHTS: Mona Shahriari, MD, FAAD, emphasized personalized AD therapy selection and highlighted OX40-targeted treatments as a promising approach that could potentially modify disease course by rebalancing immune responses.

🎥 Watch the full interview now:

Mona Shahriari, MD, FAAD, shares expert insights on tailoring atopic dermatitis care, from IL‑13 biologics to promising OX40 drugs that may modify disease long term.

06/19/2026

👥🎸 CONFERENCE HIGHLIGHTS: At , David Rosmarin, MD, highlighted emerging therapies for chronic hand , including STAT6 inhibitors and IL-2 agonists, while emphasizing the need for dedicated treatments and individualized care approaches.

🎥 Watch the full interview now: https://hubs.li/Q04m11QV0

At RAD 2026, David Rosmarin, MD, discussed the unmet need in chronic hand eczema, emerging pipeline agents, and his approach to evaluating clinical trial data.

06/18/2026

👥🎸 CONFERENCE HIGHLIGHTS: In today's session, Adam Friedman, MD, FAAD, emphasized reframing as a systemic inflammatory disease to help patients understand advanced therapies, highlighting the importance of individualized treatment and weighing the risks of undertreated disease.

🎥 Watch the full interview now: https://hubs.li/Q04l-r3R0

Drawing parallels to diabetes and hypertension, Adam Friedman, MD, invokes the dangerous side effect of doing nothing in reframing treatment strategies.

06/18/2026

👥🎸 CONFERENCE HIGHLIGHTS: At , Elaine Siegfried, MD, highlighted the need for individualized pediatric AD care, early intervention, and expanded treatment options—especially for infants younger than 6 months, who remain an area of unmet need.

🎥 Watch the full interview now: https://hubs.li/Q04lZ4-t0

Explore evolving pediatric atopic dermatitis care: personalized, stepwise therapy, early-infant treatment gaps, growth monitoring, and expanding nonsteroidal options promising better outcomes.

06/18/2026

👥🎸 CONFERENCE HIGHLIGHTS: AD’s burden extends beyond the skin, with type 2 inflammatory comorbidities, sleep disruption, and reduced quality of life affecting patients.

Adam Friedman, MD, FAAD, emphasized using comorbidity assessments to guide advanced therapy discussions.

🎥 Watch the full interview now:

Adam Friedman, MD, maps the AD comorbidity spectrum, from T2-driven diseases to sleep-related indirect consequences, and discusses clinical implications.

06/18/2026

🎸 is in full swing and we're ready for another day of exciting updates and expert insights! You may see some familiar faces from our Editorial Advisory Board - check out a preview of some of the sessions below ⬇️

As RAD kicks off in Nashville, Tennessee, scroll through and find some faces familiar to Dermatology Times who are presenting at the meeting.

06/17/2026

🌟 Catch up with more of what matters in practice at Dermatology Times NP/PA Connect - here's a quick recap of last week's headlines from Tristan Hasbargen, PA-C https://hubs.li/Q04lLztn0